Green Alpha Advisors LLC Acquires New Position in Tempus AI, Inc. (NASDAQ:TEM)

Green Alpha Advisors LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 32,283 shares of the company's stock, valued at approximately $1,090,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Federated Hermes Inc. bought a new stake in shares of Tempus AI during the second quarter worth about $19,886,000. WINTON GROUP Ltd bought a new position in shares of Tempus AI in the 2nd quarter worth $634,000. Massachusetts Financial Services Co. MA bought a new position in shares of Tempus AI in the 2nd quarter worth $28,246,000. Lingotto Investment Management LLP bought a new position in shares of Tempus AI during the 2nd quarter valued at $32,685,000. Finally, Davidson Kempner Capital Management LP purchased a new stake in Tempus AI during the 2nd quarter valued at $2,271,000. 24.22% of the stock is owned by institutional investors.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares of the company's stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David R. Epstein sold 620 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the transaction, the director now directly owns 27,894 shares of the company's stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 865,041 shares of company stock worth $35,917,673 over the last 90 days.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TEM shares. Guggenheim began coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a "buy" rating and a $74.00 price target for the company. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Loop Capital boosted their target price on shares of Tempus AI from $48.00 to $57.00 and gave the stock a "buy" rating in a report on Tuesday, October 15th. Bank of America boosted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research report on Friday, December 13th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Tempus AI Trading Down 13.8 %

Shares of Tempus AI stock traded down $5.18 during trading hours on Monday, reaching $32.34. 7,362,952 shares of the company were exchanged, compared to its average volume of 4,071,003. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The stock's fifty day moving average is $48.28 and its 200 day moving average is $47.27. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.